Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Nephrology
•
Glomerulonephritis
How do you counsel patients who are found to have a carrier mutation in a single high-risk APOL1 allele?
Related Questions
What factors do you consider when advising a patient with lupus nephritis on the safety of becoming pregnant?
Do you recommend initiating immunosuppression and plasmapheresis in patients with dialysis dependent AKI in the setting of anti-GBM disease who do not have pulmonary involvement?
How do various therapeutic approaches for IgA nephropathy target the different stages of the four-hit hypothesis?
How do you decide when to stop immunosuppression in a patient with granulomatosis with polyangiitis who is on dialysis, has not yet recovered renal function, but has shown improvement in ANCA levels?
How would you approach a patient with class III and V lupus nephritis, already on HCQ, MMF, voclosporin and losartan, but has continued proteinuria not yet attaining complete renal response?
Would you consider initiating eculizumab without plasmapheresis as initial therapy for a patient with renal TMA who has a low suspicion of TTP based on a scoring algorithm?
How would you treat idiopathic isolated renal TMA diagnosed on renal biopsy without evidence of MAHA?
Do you modify the albumin level below which you would prophylactically anticoagulate a pregnant patient with nephrotic-range proteinuria, given that hypoalbuminemia is expected in pregnancy?
What factors do you consider when deciding to treat IgA nephropathy with immunosuppression in a patient with cirrhosis, given the possibility that IgA nephropathy could be secondary to cirrhosis?
How would you approach the treatment of crescentic fibrillary glomerulonephritis?
